← Back to Search

Receptor Tyrosine Kinase Inhibitor

MGCD516 for Liposarcoma

Phase 2

Waitlist Available

Led By Matthew Ingham, MD

Research Sponsored by Matthew Ingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 33 months

Awards & highlights

Study Summary

This trial is testing a new drug to treat people with a type of cancer called liposarcoma.

Eligible Conditions

Liposarcoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 33 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 33 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 33 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression free rate

Secondary outcome measures

Adverse event rate

Overall response rate

Overall survival rate

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: MGCD516Experimental Treatment1 Intervention

Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MGCD516

2014

Completed Phase 1

~200

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Matthew InghamLead Sponsor

1 Previous Clinical Trials

1 Trials studying Liposarcoma

Mirati Therapeutics Inc.Industry Sponsor

70 Previous Clinical Trials

8,226 Total Patients Enrolled

Matthew Ingham, MDPrincipal InvestigatorColumbia University

2 Previous Clinical Trials

27 Total Patients Enrolled

1 Trials studying Liposarcoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has MGCD516 been verified by the Food and Drug Administration?

"MGCD516 was rated a 2 on the safety scales, as there is evidence of its security but no clinical data to confirm its efficacy."

Answered by AI

What is the magnitude of individuals participating in this research endeavor?

"Unfortunately, the study is no longer accepting applications. The trial opened on November 1st 2016 and was last updated 23rd of November 2022. However, there are still a plethora of opportunities for those who may have liposarcoma with 463 different studies currently recruiting patients and 16 trials looking to enrol individuals taking MGCD516."

Answered by AI

Are there any further investigations into the efficacy of MGCD516?

"At present, 16 trials are running on MGCD516 with 3 of them in their final stage. While there is a concentration of studies for this drug in New Haven, Connecticut, it's being tested at 439 distinct sites across the world."

Answered by AI

Does this clinical trial represent a pioneering approach to health care?

"Since 2015, Mirati Therapeutics Inc. have been researching the effects of MGCD516 in clinical trials. After their initial study involving 423 patients, it was approved for Phase 2 drug testing. As of today, 16 active studies are ongoing across 14 nations and 217 cities world-wide."

Answered by AI

Is this research undertaking still recruiting participants?

"Unfortunately, the clinicaltrials.gov website indicates that this trial has concluded its recruitment process. The study was first announced on November 1st 2016 and edited last on November 23rd 2022. However, there are still 479 other medical studies with open enrollment across the world today."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Matthew Ingham 2016. "Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02978859.

All > Soft Tissue Sarcoma